Study guide

8.6 Guideline-Directed Medical Therapy for Heart Failure

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

8.6 Guideline-Directed Medical Therapy for Heart Failure

Key Takeaways Explain This Topic AI

The four HFrEF pillars are ARNI or ACE inhibitor/ARB, an evidence-based beta blocker (carvedilol, metoprolol succinate, or bisoprolol only), a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor; modern practice is rapid low-dose initiation of all four followed by titration every 1-2 weeks.

An ACE inhibitor must be held 36 hours before the first dose of sacubitril/valsartan because overlapping bradykinin pathways cause angioedema; no washout is needed when switching from an ARB.

A creatinine rise of up to 30% above baseline after renin-angiotensin blockade is expected and is not a reason to stop therapy; hold for potassium above 5.5 mEq/L and use a potassium binder to preserve the regimen.

Digoxin is targeted to a serum level of 0.5-0.9 ng/mL in heart failure, and amiodarone, verapamil, dronedarone, propafenone, quinidine, clarithromycin, and cyclosporine all raise levels - halve the digoxin dose when amiodarone is started.

A chronic beta blocker should not be routinely stopped during a decompensation admission; discontinue only for cardiogenic shock, inotrope dependence, symptomatic bradycardia, or high-grade block.

Last updated: August 2026

The Four Pillars and Why Speed Now Matters More Than Sequence

Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF, ejection fraction 40% or less) rests on four foundational drug classes in the 2022 AHA/ACC/HFSA guideline. Each carries an independent mortality benefit, the benefits are largely additive, and much of the benefit appears within the first 30 days of therapy. Comprehensive four-class therapy is estimated to add several years of event-free survival compared with an angiotensin-converting enzyme (ACE) inhibitor and beta blocker alone.

Pillar Agent Starting dose Target dose Primary monitoring

ARNI (preferred) Sacubitril/valsartan 24/26 mg twice daily (49/51 twice daily if already on a moderate or high ACE inhibitor or ARB dose with adequate BP) 97/103 mg twice daily Systolic BP, potassium, creatinine, angioedema

  • or ACE inhibitor Enalapril 2.5 mg twice daily 10-20 mg twice daily Cough, angioedema, potassium, creatinine
  • Lisinopril 2.5-5 mg daily 20-40 mg daily
  • or ARB Valsartan 40 mg twice daily 160 mg twice daily Potassium, creatinine
  • Candesartan 4-8 mg daily 32 mg daily

Beta blocker Carvedilol 3.125 mg twice daily 25 mg twice daily (50 mg twice daily if over 85 kg) HR, BP, congestion; give with food

  • Metoprolol succinate 12.5-25 mg daily 200 mg daily Do not substitute metoprolol tartrate
  • Bisoprolol 1.25 mg daily 10 mg daily
  • MRA Spironolactone 12.5-25 mg daily 25-50 mg daily Potassium, creatinine, gynecomastia
  • Eplerenone 25 mg daily 50 mg daily Potassium, creatinine

SGLT2 inhibitor Dapagliflozin 10 mg daily 10 mg daily (no titration) Volume status, genital mycotic infection, euglycemic DKA

Empagliflozin 10 mg daily 10 mg daily

The modern practice change is rapid sequential initiation : get all four classes on board at low doses within days, then up-titrate every 1-2 weeks, rather than maximizing one agent before starting the next. Trial evidence supports intensive in-hospital initiation with up-titration toward full doses within about two weeks of discharge and close follow-up, which reduced 180-day readmission and death. The clinical corollary for nurses is that "the patient is not on the target dose yet" is far less concerning than "the patient is only on one pillar."

The ARNI Details the Exam Tests

Sacubitril/valsartan combines a neprilysin inhibitor with an ARB and is preferred over an ACE inhibitor or ARB in NYHA class II-III HFrEF. It may be started in hospital once the patient is hemodynamically stable, off intravenous inotropes and vasodilators, and with a systolic pressure at or above 100 mmHg.

The 36-hour washout rule. When switching from an ACE inhibitor, the ACE inhibitor must be held for 36 hours before the first sacubitril/valsartan dose. Both drugs impair bradykinin degradation - ACE inhibition blocks its breakdown and neprilysin inhibition blocks another degradation pathway - so overlapping them stacks bradykinin and produces angioedema. No washout is required when switching from an ARB , because ARBs do not affect bradykinin. A prior history of angioedema on any agent is an absolute contraindication. Also avoid in pregnancy and with aliskiren in diabetes.

Beta Blocker Initiation Rules

Only carvedilol, metoprolol succinate, and bisoprolol have mortality evidence in HFrEF. Metoprolol tartrate is not an acceptable substitute. Initiate only in a patient who is euvolemic, not inotrope-dependent, and not in an escalating diuretic phase , then double no more often than every two weeks. Warn the patient and the team about the expected transient early worsening - fatigue, mild weight gain, and slightly worse symptoms over the first 2-6 weeks - which is managed by increasing the diuretic, not by abandoning the beta blocker. Conversely, do not routinely stop a chronic beta blocker during an admission for decompensation; abrupt withdrawal is associated with higher mortality. Discontinue only for cardiogenic shock, inotrope dependence, symptomatic bradycardia, or high-grade block.